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The NZB mouse is genetically predisposed to the development of Coomb's positive 
hemolytic anemia, splenomegaly,  and, to some degree, antinuelear factors and lymph- 
oid malignancies (1). The Fx offspring of the NZB and NZW cross (B  ]W) is genetically 
predisposed to the development of antinuclear factors, anti-DNA antibodies, LE ceils, 
and a fatal lupus-like glomerulonephritis.  There is a much lower incidence of Coomb's 
positivity in this hybrid. Both strains develop lymphoid and plasma cell infiltration 
of many organs, including  the thymus. The heritable factor in these mice may not be 
any specific disease but rather a propensity to develop autoimmtmity. 
The natural history of these animals can be divided into three stages: (a) a latent 
phase from birth to about 3 months when the mice appear normal; (b) a seropathologic 
phase from 3 to  5 months when  the various autoaJatibodies  begin  to appear in the 
serum; (c) a histopathologic phase from 5 months to death when the spleen, kidney, 
thymus, and other organs show the progressive development of autoimmune lesions 
and their sequellae. There is no sharp dividing  line between these stages. The patho- 
genesis of tissue destruction in these mice is understood in part. The red cell destruc- 
tion is related to the  antibody molecules  coating the  erythroeyte surface  (2).  The 
nephritis is due to the glomerular deposition of immlme complexes, particularly DNA 
and anti-DNA (3). The mechanism for the formation of these autoantibodies is yet to 
be explained. 
Autoantibody formation may reflect the abrogation of self-tolerance.  Since  there 
is a  latent phase before autoantibodies appear, self-tolerance  may be maintained in 
NZB mice at birth and then be gradually lost. Very old mice and humans sometimes 
develop autoantibodies (4),  so that a loss of self-tolerance  appears to be an age-de- 
pendent phenomenon. This process may be greatly accelerated in NZB and B/W mice. 
We decided to investigate the potential of these mice to develop immunity 
and  tolerance  during  the  latent  phase.  Any  abnormality  discovered  at  this 
time, prior to autoantibody formation, could not be a consequence of serologic 
disease and might be related to some basic causal mechanism. We hypothesized 
that the progressive abrogation of seN-tolerance would be accompanied by an 
inability to develop or maintain tolerance to exogenously administered protein 
antigens. Ultracentrifuged bovine and human gamma globulin were selected  as 
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the  antigens  because  they  are  known  to  induce  tolerance  readily  and  repro- 
ducibly in several different mouse strains  (5,  6,  7). 
Materials and Metkods 
Animals.--Male and female NZB, NZW, B/W F~, C57B1, C3H, and Balb/c mice, 5-8 wk 
old, were procured from National Institutes of Health (NIH) inbred stock colonies.  The New 
Zealand mouse strains, although currently maintained at NIIt, were originally obtained from 
the University of Otago animal facilities in New Zealand and are in the 60th and 40th genera- 
tions for the NZB and NZW strains respectively. 
C57Bl mice were selected because of their ability to form large amounts of antibody to 
tetanus toxoid (8)  and because they occasionally develop antinuclear factor  (9). C3H mice 
were used because they neither form excessive antibody to tetanus toxoid nor demonstrate 
antinuclear factor. Finally, Balb/c mice were chosen because they develop plasma cell tumors 
in response to intraperitoneal Bayol F and because they are known to produce large quantities 
of antibody (8, I0). 
Antigens.--Bovine gamma globulin (BGG) (Armour Pharmaceutical Company, Kankakee, 
Ill.), human gamma globulin (HGG) (Mann Research Laboratories, Inc., New York), and egg 
albumin  (Ea)  crystallized  X  2  (Worthington  Biochemical Corporation,  Freehold,  N.  J.) 
served as protein antigens. 
Protein Zabding  with 131I.--The method of  labeling was a  modification from McFarlane 
(11). Assuming a labeling efficiency of 33%, 3 mc of carrier-free and reducing agent-free mI 
(E. R. Squibb & Sons, New York) was added to 10 mg of BGG or HGG in 0.5 cc borate buffer, 
pH 8.0.  ICl (0.033 ~s) was added rapidly to a final concentration  of 2.45  X  l0 smg I/mg. 
IgG in a final volume of 2.0-2.5 cc. After labeling, dialysis of the sample against five to seven 
changes of 0.15 ~r NaC1 over 48-72 hr was carried out and  the amount of radioactivity pre- 
cipitable with 20% phosphotungstic acid was shown to be greater than 98%. In this manner, 
it was possible  to label 10 #g of IgG with from 0.3  to 0.7 pc 131I. 
Pretreatment.--On  day zero, seven to nine mice from each strain received intraperitoneal 
(i.p.)  injections of Ea (12 rag), BGG (0.001, 0.02,  5, 9, 15, or 24 rag), or HGG (1, 12, or 24 
rag) dissolved in phosphate buffered saline, pH 7.2. The animals receiving  Ea served as specific- 
ity controls and developed antibody titers comparable to saline-injected control mice. Prior 
to injection, proteins were ultracentrifuged in a  Spinco 40 rotor at 40,000  rpm  (105,000  g) 
for 30 rain at 20°C.  Subsequent protein determinations were carried out in a Beckman DU 
spectrophotometer using: 
l%  _  1% 
E~s0mg,pHT.0-  13.0 (BGG) (12), E~s0ra~,pHT.0 =  14.3 (ItGG)  (13) 
1% 
and E2STm,,0.1S.N,OH =  7.39 (Ea) (13). 
From 6-30% of the starting material was sedimented by the ultracentrifugation. 
Challenge.--On day 12, mice were challenged with either BGG or HGG, 10 mg/cc, emulsified 
with an equal volume of complete Freund's adjuvant  (Difco Laboratories, Detroit, Mich.). 
Each animal received 0.05 cc into each of four footpads for a total dose of 1.0 mg per mouse. 
A control group of mice was left unchallenged. 
x31I Immune Elimination.--Starting  on day 22,  the elimination of an i.p.  tracer  dose  of 
10/tg of l~I-labeled BGG or of 20/tg of mI-labeled HGG was followed for each mouse in a 
whole body Baird Atomic Counter.  3  days prior to the  administration  of the radioactive 
tracer all mice were given 0.1% KI in their drinking water. Final elimination curves were 
determined after correction for background, radioactive decay, and machine variability. 
ttemagglutinatgon.--Animals  given HGG were bled on days 28 and 40; animals given BGG PARKER  ~'.  STAPLES  AND  NORMAN  TALAL  125 
were bled on days  12 and 40. Hemagglutination titers were determined by standard  micro- 
hemagglutination methods  using a  formatinized  tanned  sheep ceil assay (14,  15). All scra 
from  a  single bleeding were  run on  the same day; positive sera of known titer and known 
negative sera were included with each assay. 
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Fro. 1. Elimination of 10/~g 1sII-BGG by C3H mice 10 days postchsllenge. Data are plotted 
as per cent retained radioactivity against time in days for varying pretreatment doses of BGG. 
Each point in this and other figttres represents average values for five to seven mice. 
Purif~  of Antigen for Hemagglc4ination.--Beeanse of the we[I-known contamination 
ofcommercialBGGbysmallamountsof  a ~-globulin (16), theBGG used to coat tanned sheep 
red blood cells was first purified by starch block electrophoresis (17). Crude ]]GO, 200--400 
rag, was added to a  1 X  46 X  30 cm staxch block and eleetrophorcsed in barbital buffer, pH 
8.6, for 48 hr at a potential of 450 v. Protein was then eluted from 1 cm strips of starch and 
Lowry protein determinations (18)  carried out. The protein in the slowest two-thirds of the 126  INABILITY  TO  INDUCE TOLERANCE IN  NZB  MICE 
w-region was dialyzed against cold 0.85% NaC1 for 48 hr,  and concentrated to  10 mg/cc. 
Immunoelectrophoresis against a rabbit anticrude BGG antiserum showed that the t~-globulin 
present in the crude BGG preparation had been entirely eliminated. 
HGG (Mann Fine Chemicals, Inc., New York), certified  to be chromatographically pure, 
was also tested at 10 mg/cc against a known rabbit antiwhole human serum and was found 
I00 
~q 
~.9.0mg  BGG 
co  ~.  )4.0rag BGG 
(.9 
nn 
~_  I0-  I 
Z 
"'  "  / 
,,,  / 
o_  ~  5.0  mg BGG 
\ 
\ 
\ 
\ 
\ 
I  ~  I  I  I 
I  2  3  4 
DAYS 
FIG. 2, E]imination  of 10 #g ~II;B~  by C57BI  mice I0 days  postchaJ1enge. 
to contain no demonstrable contaminant. Therefore, it was used directly, without furthex 
purification, to coat sheep red blood cells. 
RESULTS  laI-BGG  Elimination.--In  the  first  experiment,  NZB,  B/W,  NZW, C57Bl, 
and C3H mice were pretreated with 0.001, 0.02, or 5  mg of soluble BGG.  In a PA~R  J. STAPLES AND I~ORMAN  TALAL  127 
second experiment, NZB, B/W, and C57B1 animals were given 9, 15, and 24 mg 
of soluble BGG. 
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FIos. 3. and 4. !ram,me elimination 10 days poste&allenge for NZB 0eft) and B/W F~ 
(right) mice given maximum pretreatmeaxt  doses of soluble BGG. 
Fig. 1 shows elimination data (plotted as per cent retained radioactivity) for 
C3H mice studied  10 days postchallenge. When pretreated with  1/~g BGG, 
these  animals  showed immune  elimination comparable to  that  seen in  Ea- 
~etr~ted controls. However, 0.02 and 5 mg of BGG pretreatment led to pro- 128  INABILITY  TO  INDUCE  TOLERANCE  IN  NZB  MICE 
gressive  nonimmune  elimination  approaching  that  of  untreated  mice.  Non- 
immune elimination was also observed in C57B1 mice (Fig. 2). Here, however, 
higher pretreatment doses of 9  and 24 mg BGG were required to obtain non- 
immune elimination  curves comparable to that  seen in  the  C3H mice. 
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By contrast, Figs. 3 and 4 show results of 13~I-BGG elimination for the NZB 
and B/W  F1 strains given maximum pretreatment doses of 9  and 24 rag. All 
animals  showed  rapid  immune  elimination  comparable  to  NZB  and  B/W 
mice pretreated with Ea. There was no evidence for high dose tolerance. Lower IO-  ¢q 
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pretreatment doses of 0.001,  0.02,  and 5 mg BGG (not shown)  resulted in no 
evidence for low dose tolerance. NZW mice given 5 mg BGG (also not shown) 
showed partial nonimmune elimination curves (30 and 18 % retained radioactiv- 
ity at !  and 2 days) but were not tested at higher dose levels. 
TABLE I 
4 Wk Hemagglutination Titers (log~)  for Individual Mice 
Experimen~ 1 
Dose 
mg 
5.0 
0.02 
0.001 
5.0 
Mean 
titers~ 
8.2 
6.7 
4.0 
0.8 
1.3 
7.4 
6.2 
2.6 
2.0 
2.9 
7.9 
7.7 
5.8 
5.0 
5.0 
8.4 
8.1 
5.4 
5.3 
6.0 
* Number of mice having individual (log~) fiters. 
:~ Average (log~) titer by strain. 
Comparative strain data are summarized in Fig. 5 in which the minimal doses 
of antigen which resulted in tolerance in the C3H and C57B1 mice are contrasted 
with  the  higher  and  maximal doses  of  antigen  which  resulted  only in  non- 
tolerance  in  NZB  and  B/W  mice. 
BGG-Hemaggtutination.--Assays  of serum obtained just  prior  to  challenge 
with  BGG  in  adjuvant  were  negative for  all  strains,  indicating  no  immune 
response to the pretreatment doses of BGG. However, assays 4  wk postchal- PARKER .]'.  STAPLES  AND  NORMAN  TALAL  131 
lenge confirmed the lack of tolerance induction in the NZB and B/W mice.As 
shown in Fig. 6, increasing pretreatment doses of ultraeentrifuged BGG led to 
a generally progressive suppression of antibody titers in the C3H, C57B1, and 
NZW strains.  This was most striking in C3H and C57B1 mice, and especially 
so in those animals receivingthe highest dose of BGG (5 rag). By contrast, there 
was no significant fall in antibody titers in NZB or B/W mice. 
Fig. 7 shows similar results for the experiment in which maximum pretreat- 
ment doses of BGG were used while Tables I  and II summarize  the hemag- 
glutination data for individual mice for all doses. Once again, the C57B1 mice 
were fully tolerant at this time, showing virtually no antibody formation at 
TABLE II 
4 Wk Hemagglutinal~n  Titers (log~)  for Individual  Mice 
Experiment 2 
Dose 
mg 
), 15, and 
24 
14 
Antigen 
BGG 
Ea 
Strain 
NZB 
B/W 
C57B1 
NZB 
B/W 
C57B1 
12 
2 
Hemagglutination titers* 
345678 
125711 
11455 
1 
21 
1  1 
123 
9  I0  11 
3 
3 
Mean 
fiters~ 
5.3 
6.7 
0.7 
8.1 
8.2 
5.4 
* Number of mice  having  individual  (log~) titers. 
Average (log2) titer by strain. 
any pretreatment dose. On the other hand, NZB and B/W mice showed only a 
mild depression of antibody formation at 9,  15,  and 24 nag, this  depression 
being most marked in the NZB pretreated with 15 rag. 
An additional observation was that consistently higher titers (two to three 
tubes)  were observed  in Ea-pretreated, immunized NZB  and B/W mice,  as 
compared with the other three strains. This suggests  that, in addition to a 
relative lack of tolerance induction, NZB and B/W mice may produce quantita- 
tively more antibody to a standard 1 mg BGG challenge and to a 10/~g booster 
(the mI-BGG) than do other mouse strains. While these higher titers for stand- 
ard challenge in the NZB mouse might reflect only an increased  amount of 
antibody, this possibility  was ruled out by incubating positive  NZB and 
B/W sera with 2-mercaptoethanol  and retesting.  No ME-sensitive  antibody 
was found. 132  ~n:rrY  TO INDUCE  TOLERANCE  IN  NZB MICE 
13'I-ttGG E.limination.--In  an attempt to confirm the lack of tolerance induc- 
tion in NZB and B/W mice, a second protein antigen (ultracentrffuged HGG) 
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FIG. 8. Elimination of 20/~g ~tI-HGG 10 days postchallenge in mice pretreated with 12 
mg soluble HGG. 
was studied.  Pretreatment doses of  1.0,  12,  and 24 mg were given to NZB, 
B/W,  C3H,  and Balb/c mice. 
Fig. 8 presents the 10 day postchallenge elimination data for all strains given 
12 mg HGG and is representative of results seen with both the lower 1.0 mg and 
the higher 24 mg antigen doses.  C3H mice showed a  noniinmune elimination, ,2[ 
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extending Golub and Weigle's observations  I of a similar ease of tolerance induc- 
tion with 0.5-1.0  mg soluble HGG  in C57B1,  A/Jax,  and DBA/2  strains.  In 
contrast, NZB and B/W mice showed striking immune elimination curves even 
when  pretreated with  24 mg HGG.  However,  the Balb/c strain also showed 
TABLE III 
2 Wk Hemagglugination Titers (log2) for Individual  Mice 
Ezperiment 3 
Dose  Antigen Strain 
mg 
24  HGG 
12  HGG 
1  HGG 
12  Ea 
Untreated 
Hemagglutination  titem* 
0  i I  2  3  4  5  6  7  8  9  10  11 
NZB  1  2  3 
B/W  1  4  1 
Balb/c  1  3  2 
C3H  1  3 
NZB  1  1  3 
B/w  2  i  1 
Balb/c  1  1  3 
C3H  4  1  1 
NZB  3  3 
B/W  2 
Balb/c  2  1  4 
C3H  1  2  1  2  1 
NZB  1  1  4  1 
B/W  3  2 
Balb/c  3  3 
C3H  4  2 
NZB  I  2  3 
B/W  4  1  1 
Balb/c  3  1  3 
C3H  2  2 
~e~.n 
titers~ 
12  13 
10.6 
1  10.3 
7.0 
3.8 
12  10.6 
1  10.2 
7.4 
4,5 
10.5 
4  1  11.9 
8.3 
6.0 
9.7 
9.4 
8.5 
7.3 
2.1 
0.9 
1.3 
3.5 
* Number of mice having individual (log2) fiters. 
:~ Average (log~) fiter by strain. 
fairly prompt elimination at  all pretreatment  doses  and  in  this  respect was 
more like the NZB and B/Wstrains than any other mouse strain tested thus far. 
ttGG-Hmaegglutination.--Hemagglutination  data (Figs. 9  and  10)  obtained 
2  and 4 wk postchallenge revealed several important differences from the data 
presented in the previous BGG studies. 
1 Golub, E. S., and W. O. Weigle. 1967. Unpublished  observations. pARKER  ~'.  STAPLES  AND  NORMAN  TALAL  135 
Most control mice neither pretreated nor challenged with HGG made a weak 
antibody response to the 20/~g 131I-HGG booster. This, taken with the fact that 
antibody titers were two to three tubes higher in Ea-injected control  mice 
immunized with HGG than were antibody titers of control mice immunized 
with BGG, suggested that HGG was a better immunogen and therefore  per- 
haps a weaker  tolerogen than was BGG. 
A second difference was that although both Balb/c and C3H mice pretreated 
with 12 and 24 mg HGG appeared to show a slight depression of antibody  forma- 
tion, there was never the marked depression  of antibody production seen in 
BGG-pretreated control  strains (cf. Fig. 6).  This again indicated that HGG 
may be a stroger immunogen than BGG. 
The major finding, however, was that NZB  and B/W mice showed no evi- 
dence of tolerance to a second protein antigen.  As individual data from Table 
III show, no NZB or B/W mouse pretreated with HGG had an antibody titer 
of less than nine. This was true both 2 and 4 wk postchallenge. 
Finally, nonpretreated, immunized (Fig.  9  and  10)  NZB  and B/W mice 
were again found to have antibody titers two to three tube dilutions higher 
than comparably immunized Balb/c and C3H mice. Moreover, NZB and B/W 
mice pretreated with 1 mg of HGG and studied at 2 wk showed greater quanti- 
ties of antibody when compared to their Ea-treated counterparts. 
DISCUSSION 
We studied six mouse strains and found considerable variation in their ability 
to produce  antibody and develop tolerance  to BGG and HGG. Three  strains 
(C3H, C57BI, and NZW) made a comparable amount of antibody to a standard 
antigenic challenge and could be rendered tolerant readily. Two strains (NZB 
and B/W) made significantly greater quantities of antibody and were extremely 
resistant to tolerance induction.  Finally, a sixth strain (Balb/c) resembled the 
C3H,  C57Bl, and NZW with respect  to amount of antibody produced but 
resembled the NZB and B/W with respect to difficulty of tolerance induction. 
The lymphoid system has the capacity for the simultaneous development of 
immunity and tolerance (19), but which event ultimately  predominates depends 
on many factors. These include the nature, dose, and route of administration of 
antigen, as well as the immunologic maturity, number of both antigen-process- 
ing and antibody-forming cells, and species of animal used.  The net result of 
antigen administration is probably a balance between antibody production and 
tolerance, yet it may be di~cult to achieve or detect tolerance under conditions 
which greatly favor antibody production. 
The relative lack of tolerance  observed in the NZB  and B/W mice could 
reflect an abnormality in either the afferent or the efferent portion of the im- 
mune system, tending to favor an immune response to an antigen which, in 
other strains,  was tolerogenic, The antigens used in our studies were ultracen- 136  INABILITY  TO  INDUCE  TOLERANCE  IN  NZB  MICE 
trifuged heterologous gamma globulins which produce a state of unresponsive- 
ness because  they are probably poorly phagocytized by ceils of the reticulo- 
endothelial system (20). The nonphagocytized antigen may then interact directly 
with receptors on the lymphocyte to induce  a state of immunologic unrespon- 
siveness. 
If the reticuloendothelial  system of the NZB and B/W mice was unusually 
active and capable of phagocytizing soluble protein antigens which would not 
ordinarily be ingested because of their physical state, then the antigen would 
be processed normally and presented to the lymphoid cells in a way leading  to 
an immune response. This explanation  would  seem to  apply to  the Balb/c 
strain, for Golub and Weigle have produced tolerance in this strain after salt 
fractionation of HGG to yield a greater concentration of monomers (21). 
On the other hand, the relative lack of tolerance in the New Zealand strains 
might be due to an abnormality of the efferent arc of the immune response. 
Viewed in this way, soluble antigen might, upon contact with immunologically 
competent but abnormal small lymphocytes, either have no effect at all, prime 
them for subsequent challenge, or actually commit them to a low grade immune 
response. We could detect no antibody following treatment with ultracentri- 
fuged BGG, although a small amount of antibody could have escaped detection. 
The increased amounts of antibody formed in response to pretreatment with 1 
mg of HGG and later challenge with that  antigen may mean that  the mice 
were primed by the ultracentrifuged HGG. This point is worthy of further 
study. 
The concept that immunologicaUy competent cells  might be committed in an 
immune rather than an unresponsive direction  could explain the development 
of autoimmunity as a consequence  of immunization of lymphocytes by small 
amounts of selLantigen over time. This would imply that immunocytes either 
become capable of initiating  an autoimmune  response autonomously  or that 
the influence  of some regulatory  mechanism necessary for suppression or modi- 
fication of potentially autoreactive cells  is ddective. A  potential site  for the 
generation of self-tolerant  cells  and for the elimination of autonomous,  auto- 
reactive cells  is the thymus, a central  lymphoid organ known to be necessary 
for tolerance  induction (22)  as well  as escape  from tolerance  (23). 
A  functional abnormality of the NZB  thymus may be related to lack of 
tolerance induction. DeVries and HJjmans  (24) described changes in thymic 
epithelial  cells  and Hassall's  corpuscles  in young NZB  and B/W  mice during 
the latent phase of their  disease  prior  to the onset of serologic  abnormalities. 
Neonatal thymectomy  in NZB  mice did not delay the onset of autoimmune 
hemolytic  anemia or Coomb's positivity  but rather hastened  them (25, 26), 
while thymectomy in rabbits  (27)  and Swiss mice (28)  led to the development of 
Coomb's positive reactions and antinuclear autoantibodics respectively. It is 
therefore tempting to speculate  that  the thymic histologic  changes in NZB  and PARKER J.  STAPLES AND NORMAN TALAL  137 
B/W mice have  as  a  functional counterpart the  loss  of  a  thymic function 
necessary for the induction of both experimentally induced and self-tolerance. 
Of the three mouse strains relatively resistant to tolerance induction, two 
(NZB and B/W) are predisposed to autoimmune disorders and two (NZB and 
Balb/c) to lymphomas (29) and plasmacytomas (10). Thus it is worth consider- 
ing that the immunologic hyperresponsiveness in the NZB  and B/W strains 
and the relative lack of tolerance to protein antigens in all three strains reflect 
an altered immunologic mechanism(s) ultimately responsible  for the develop- 
ment of lymphoid malignancies. Viral particles  resembling the C-particles of 
murine leukemia are present in NZB mice (30).  Mice infected with lactic dehy- 
drogenase virus  produce  antibody to  a  normally tolerogenic  dose  of  HGG 
(31). Thus the virus of NZB mice, if it is an etiologic agent in NZB disease, may 
be acting in a manner analogous to LDH virus  to alter the balance between 
immunity and tolerance. 
Although we have demonstrated that adult NZB and B/W mice do not be- 
come tolerant by conventional methods to soluble BGG or HGG, this does not 
imply that NZB mice are incapable of being rendered tolerant by other methods 
or to other antigens. The fact that we and others have induced tolerance to 
heterologous gamma globulins in six strains of mice (see reference 7 and foot- 
note 1) suggests that additional strains, when studied, may also become toler- 
ant more readily than NZB and B/W mice. 
Since autoantibodies inthe NZB  are  absent at birth and appear  after a  3 
month latent period, NZB and B/W mice may initially develop self-tolerance 
which is gradually lost. If so, it should be possible to induce tolerance to exog- 
enous antigens in newborn or very young NZB mice, then follow the rate at 
which this tolerance disappears.  Such  experiments  are  currently in  progress 
and it will be interesting to see if the relative inability to induce tolerance as 
described in this report will correlate with a rapid loss of possible preexisting 
tolerance. 
SUMMARy 
Immunologic tolerance  to  ultracentrifuged bovine  gamma globulin  could 
not be induced in 6-wk old NZB or B/W mice, but developed readily in C3H, 
NZW, and C57B1 mice. NZB and B/W mice, as well as Balb/c mice, failed to 
become tolerant to ultracentrifuged human gamma globulin. The NZB  and 
B/W mice also showed higher antibody titers to a  standard antigenic chal- 
lenge.  This immunologic hyperreactivity and lack of experimental tolerance 
may be related to the lack of self-tolerance, autoimmunity, and lymphomas that 
develop in these mice at a later age. 
We are indebted to Dr. C. T. Hansen, Mr. W. J. McEleny, and Mr. W. Hinlde for the 
establishment and maintenance  of the NZB, NZW, and B/W colonies and to Dr. Thomas 
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